12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers Milestone Scientific (AMEX:MLSS) shares moved upwards by 4.7% to $0.3 during Friday’s after-market session. The market value…
Novel Approach To Treating Advanced Liver Cancer With Namodenoson Published In Leading Scientific Journal: 12-Month Survival Of 44% For Namodenoson Vs. 18% For Placebo
Namodenoson is being evaluated in a pivotal Phase III study
Namodenoson is approved for compassionate use in the treatment of liver cancer in Israel and Romania
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CFBI), a
Can-Fite’s Namodenoson Increases Survival For Most Severe Patients With Advanced Liver Cancer
Can-Fite BioPharma Ltd (NASDAQ:CANF) provided an update on its clinical program for Namodenoson for hepatocellular carcinoma (HCC). At two upcoming conferences,…
Can-Fite BioPharma To Present Liver Cancer Data At Upcoming Conferences
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today provided an update on
Can-Fite Reports New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented By KOL Dr. Papp At The 31st European Academy Of Dermatology
Dr. Papp: "The safety results on Piclidenoson and its progressive effectiveness over the study period position it as unique among the current treatment options especially given the chronic nature of psoriasis
Can-Fite Announces Piclidenoson Is Set To Enter Clinical Trial For Treatment Of Osteoarthritis In Dogs Efficacy Trial To Commence And Financially Covered By Vetbiolix
Safety study successfully completed; efficacy trial to commence and financially covered by Vetbiolix
Canine osteoarthritis market is projected to reach $3 billion by 2028
PETACH TIKVA, Israel--(BUSINESS WIRE)--